Last reviewed · How we verify
Lourdes Montero Cruces — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Buckberg Cardi-Braun | Buckberg Cardi-Braun | marketed | ||||
| Custodiol Htk Soln | Custodiol Htk Soln | marketed | Organ preservation solution | Transplantation |
Therapeutic area mix
- Transplantation · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Dr. F. Köhler Chemie GmbH · 1 shared drug class
- Marc Sakwa, MD · 1 shared drug class
- RenJi Hospital · 1 shared drug class
- Rigshospitalet, Denmark · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Lourdes Montero Cruces:
- Lourdes Montero Cruces pipeline updates — RSS
- Lourdes Montero Cruces pipeline updates — Atom
- Lourdes Montero Cruces pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Lourdes Montero Cruces — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/lourdes-montero-cruces. Accessed 2026-05-16.